针对RAS上游和下游的信号通路,用于癌症治疗
1Department of Pharmacy, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj, 8100, Bangladesh.
European journal of pharmacology
|June 12, 2024
概括
抑制RAS/RAF/MEK/ERK (MAPK) 和PI3K-Akt-mTOR通路的向疗法在癌症治疗中表现有前途. 针对特定蛋白质的小分子抑制剂提供了针对各种癌症的有希望的策略,包括肺癌,乳腺癌和血液恶性瘤.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 癌症经常涉及过度激活的RAS/RAF/MEK/ERK (MAPK) 和PI3K-Akt-mTOR信号通路,通常是由遗传突变驱动的.
- 向疗法通过抑制这些途径中的特定蛋白质,为癌症治疗提供了一个有希望的策略.
- RAS,RAF,PTEN和PIK3CA基因的突变是这些异常信号通路的常见驱动因素.
研究的目的:
- 审查针对RAS上游和下游信号通路中的特定蛋白质的小分子抑制剂.
- 提供针对各种癌症的向疗法的疗效概述.
- 突出抑制癌症治疗关键信号分子的潜力.
主要方法:
- 对向RAS/MAPK和PI3K-Akt-mTOR通路的小分子抑制剂的文献综述.
- 对包括RTK抑制剂,Farnesyl转移酶抑制剂和下游信号抑制剂在内的向疗法研究的分析.
- 对针对RAF,MEK,PI3K,AKT和mTOR的抑制剂的临床结果的检查.
主要成果:
- RTK抑制剂 (例如,伊马替尼,阿法替尼) 在非小细胞肺癌中显示出有效性.
- RAF 抑制剂 (例如,维穆拉芬尼布) 和 MEK 抑制剂 (例如,美替尼布) 对具有 BRAF-V600E 突变的癌症有效.
- PI3K,AKT和mTOR通路的抑制剂在侵袭性乳腺癌,淋巴瘤,新生体和血液恶性瘤中表现出有效性.
结论:
- 针对RAS和PI3K-Akt-mTOR通路中的特定蛋白质的小分子抑制剂为各种癌症提供了有效的治疗策略.
- 针对性抑制关键信号分子显示出有前途的抗瘤活性,无论是体外还是体内.
- 进一步开发这些向疗法具有改善癌症治疗结果的巨大潜力.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
MAPK Signaling Cascades
5.4K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.4K
Small GTPases - Ras and Rho
3.9K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
3.9K


